128 results
Page 4 of 7
8-K
EX-99.1
q6adosagwvygjf8
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
424B5
qk2av7xhd7qil2 ng
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
gh3np075xzsk566945d
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
3ethh 08az7oxj
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
8eq r6kp5
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
fz10rk5khpy1eyhji8
13 Jan 20
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
7:09am
8-K
EX-10.1
etc8 inyb9lu
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
ha9drhnfxsxw
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
z3jlbmh ft5zwwa3qcp
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
nwut5j8
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-99.1
hm3 1pw2vn1owp11a35
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am